{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:17:40Z","timestamp":1785428260215,"version":"3.56.0"},"reference-count":30,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ICI22\/00090"],"award-info":[{"award-number":["ICI22\/00090"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"award":["ICI22\/00090"],"award-info":[{"award-number":["ICI22\/00090"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}]},{"name":"European Union NextGenerationEU\/PRTR"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Chronic kidney disease (CKD) is associated with early disturbances in mineral metabolism that contribute to bone fragility. Secondary hyperparathyroidism is a key component of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD) and may affect bone even during the early stages of CKD. This study evaluated the association between serum parathyroid hormone (PTH) concentrations and bone mineral density (BMD) in patients with stage 3 CKD. Methods: A multicenter cross-sectional observational study was conducted in 203 patients with stage 3 CKD. Blood and 24 h urine samples were collected to measure creatinine, calcium, phosphate, magnesium, 25-hydroxyvitamin D, fibroblast growth factor 23 (FGF23), and PTH. Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA). Associations between serum PTH concentrations and BMD were analyzed. Results: Elevated serum PTH concentrations were associated with lower femoral BMD and less favorable femoral T-scores, whereas no significant associations were observed at the lumbar spine. Serum PTH concentrations were inversely correlated with femoral BMD and femoral T-scores. Patients with reduced femoral BMD also showed higher FGF23 concentrations and lower renal function, while serum calcium, phosphate, magnesium, and 25-hydroxyvitamin D concentrations did not differ significantly among the groups. Conclusions: Elevated serum PTH concentrations were associated with reduced femoral BMD in patients with stage 3 CKD, supporting preferential early involvement of cortical bone. Serum PTH may represent an accessible biomarker for the early identification of patients at increased risk of cortical bone loss before conventional biochemical abnormalities become clinically apparent.<\/jats:p>","DOI":"10.3390\/jcm15145519","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:05:58Z","timestamp":1784077558000},"page":"5519","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Serum Parathyroid Hormone Levels and Femoral Bone Mineral Density in Patients with Chronic Kidney Disease Stage 3"],"prefix":"10.3390","volume":"15","author":[{"given":"Laura","family":"Monta\u00f1o-Azor","sequence":"first","affiliation":[{"name":"Multiprofessional Teaching Unit for Family and Community Care of C\u00f3rdoba, 14011 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Cant\u00f3n Guerrero","sequence":"additional","affiliation":[{"name":"Palma del R\u00edo Health Center, Andalusian Health Service, 14700 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Jim\u00e9nez S\u00e1nchez","sequence":"additional","affiliation":[{"name":"C\u00f3rdoba Guadalquivir Health District, Andalusian Health Service, 14011 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Jim\u00e9nez Moral","sequence":"additional","affiliation":[{"name":"Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8502-3564","authenticated-orcid":false,"given":"Raquel Mar\u00eda","family":"Garc\u00eda-S\u00e1ez","sequence":"additional","affiliation":[{"name":"Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain"},{"name":"Nephrology Service, Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"},{"name":"University of Cordoba, 14004 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3696-582X","authenticated-orcid":false,"given":"Mar\u00eda Encarnaci\u00f3n","family":"Rodr\u00edguez-Ortiz","sequence":"additional","affiliation":[{"name":"Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain"},{"name":"Nephrology Service, Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"},{"name":"University of Cordoba, 14004 Cordoba, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS), Carlos III Health Institute, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9380-6614","authenticated-orcid":false,"given":"Mariano","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain"},{"name":"University of Cordoba, 14004 Cordoba, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS), Carlos III Health Institute, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7647-9391","authenticated-orcid":false,"given":"Victoria","family":"Pend\u00f3n-Ruiz de Mier","sequence":"additional","affiliation":[{"name":"Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain"},{"name":"Nephrology Service, Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"},{"name":"University of Cordoba, 14004 Cordoba, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS), Carlos III Health Institute, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Romero-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"C\u00f3rdoba Guadalquivir Health District, Andalusian Health Service, 14011 Cordoba, Spain"},{"name":"Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain"},{"name":"University of Cordoba, 14004 Cordoba, Spain"},{"name":"Carlos Castilla del Pino Health Center, Andalusian Health Service, 14011 Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.kint.2020.02.010","article-title":"Nomenclature for kidney function and disease: Report of a KDIGO consensus conference","volume":"97","author":"Levey","year":"2020","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00223-020-00777-1","article-title":"Chronic Kidney Disease\u2013Mineral and Bone Disorders: Pathogenesis and Management","volume":"108","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Williams, M.J., White, S.C., Joseph, Z., and Hruska, K.A. (2023). Updates in the chronic kidney disease-mineral bone disorder show the role of osteocytic proteins, a potential mechanism of the bone\u2013vascular paradox, a therapeutic target, and a biomarker. Front. Physiol., 14.","DOI":"10.3389\/fphys.2023.1120308"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hu, L., Napoletano, A., Provenzano, M., Garofalo, C., Bini, C., Comai, G., and La Manna, G. (2022). Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012223"},{"key":"ref_6","unstructured":"Patel, P., and Hashmi, M.F. (2026, July 08). Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD), StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560742\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5414\/CNP65235","article-title":"Renal osteodystrophy: What\u2019s in a name? Presentation of a clinically useful new model to interpret bone histologic findings","volume":"65","author":"Malluche","year":"2006","journal-title":"Clin. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ki.2008.264","article-title":"Chronic kidney disease and bone fracture: A growing concern","volume":"74","author":"Nickolas","year":"2008","journal-title":"Kidney Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrneph.2016.164","article-title":"The Role of Phosphate in Kidney Disease","volume":"13","author":"Vervloet","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2215\/CJN.04100808","article-title":"Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA","volume":"4","author":"Ix","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11154-017-9421-4","article-title":"Secondary Hyperparathyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies","volume":"18","year":"2017","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Raju, S., and Saxena, R. (2025). Hyperphosphatemia in Kidney Failure: Pathophysiology, Challenges, and Critical Role of Phosphorus Management. Nutrients, 17.","DOI":"10.20944\/preprints202503.2193.v2"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ki.2012.176","article-title":"Update on fibroblast growth factor 23 in chronic kidney disease","volume":"82","author":"Wolf","year":"2012","journal-title":"Kidney Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8821292","DOI":"10.1155\/2021\/8821292","article-title":"FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease","volume":"2021","author":"Kurpas","year":"2021","journal-title":"Dis. Markers"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Figurek, A., Rroji, M., and Spasovski, G. (2023). FGF23 in chronic kidney disease: Role in bone and cardiovascular risk. Cells, 12.","DOI":"10.3390\/cells12040609"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3803\/EnM.2024.1978","article-title":"Roles of Parathyroid Hormone and Fibroblast Growth Factor 23 in Advanced Chronic Kidney Disease","volume":"39","author":"Nakagawa","year":"2024","journal-title":"Endocrinol. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","article-title":"European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4\u2013G5D","volume":"36","author":"Evenepoel","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"(2017). Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD\u2013MBD. Kidney Int. Suppl., 7, 1\u201359.","DOI":"10.1016\/j.kisu.2017.10.001"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.5301\/jn.5000187","article-title":"Bone-vascular cross-talk","volume":"25","author":"London","year":"2012","journal-title":"J. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.ackd.2019.09.006","article-title":"Bone-Vascular Axis in Chronic Kidney Disease","volume":"26","author":"Evenepoel","year":"2019","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_23","first-page":"597","article-title":"Bone mass density measurement in chronic kidney disease","volume":"21","author":"West","year":"2012","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2215\/CJN.12871211","article-title":"Bone mineral density and fracture risk in older individuals with CKD","volume":"7","author":"Yenchek","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_25","first-page":"803","article-title":"Skeletal effects of parathyroid hormone excess","volume":"47","author":"Cusano","year":"2018","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/bonekey.2014.37","article-title":"Chronic Kidney Disease and Osteoporosis: Evaluation and Management","volume":"3","author":"Miller","year":"2014","journal-title":"BoneKEy Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2215\/CJN.03850609","article-title":"Control of Secondary Hyperparathyroidism by Vitamin D Receptor Agonists in Chronic Kidney Disease","volume":"5","author":"Sprague","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_30","unstructured":"World Health Organization (1994). Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis, WHO. WHO Technical Report Series."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5519\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:33:23Z","timestamp":1785141203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":30,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145519"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145519","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}